Page 7 - Brian Markison News Today : Breaking News, Live Updates & Top Stories | Vimarsana

About Osmotica Pharmaceuticals plc Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. RVL Pharmaceuticals, Inc. is the Company's ophthalmic subsidiary supporting UPNEEQ. Vertical Pharmaceuticals, LLC represents the Company's diversified branded portfolio and Trigen Laboratories, LLC represents the Company's non-promoted products, including complex generic formulations. Osmotica has operations in the United States, Argentina, and Hungary. In...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Osmotica to Present at 10th Annual SVB Leerink Global Healthcare Conference Osmotica Holdings US LLCFebruary 18, 2021 GMT BRIDGEWATER, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the 10th Annual SVB Leerink Global Healthcare Conference as follows: Date: W...

Osmotica Pharmaceuticals plc Receives Complete Response Letter from U.S. Food and Drug Administration for Arbaclofen Extended Release Tablets Osmotica Holdings US LLC Bridgewater, New Jersey, UNITED STATES BRIDGEWATER, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (“CRL”) regarding the Company's New Drug Application (“NDA”) seeking approval for the investigational agent arbaclof...